| Literature DB >> 34959606 |
Eduarda M P Silva1,2, Luisa Barreiros2,3, Sara R Fernandes2,3, Paula Sá4, João P Prates Ramalho5,6,7, Marcela A Segundo2.
Abstract
The quantitative analysis of pharmaceuticals in biomatrices by liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) is often hampered by adduct formation. The use of the molecular ion resulting from solvent adducts for quantification is uncommon, even if formed in high abundance. In this work, we propose the use of a protonated acetonitrile adduct for the quantitative analysis of tranexamic acid (TXA) by LC-MS/MS. The high abundance of the protonated acetonitrile adduct [M + ACN + H]+ was found to be independent of source-dependent parameters and mobile phase composition. The results obtained for TXA analysis in clinical samples were comparable for both [M + ACN + H]+ and [M + H]+, and no statistically significant differences were observed. The relative stability and structure of the [M + ACN + H]+ ions were also studied by analyzing probable structures from an energetic point of view and by quantum chemical calculations. These findings, and the studied fragmentation pathways, allowed the definition of an acetimidium structure as the best ion to describe the observed acetonitrile protonated adduct of TXA.Entities:
Keywords: analyte quantification; collision-induced dissociation; electrospray ionization; fragmentation; solvent adducts
Year: 2021 PMID: 34959606 PMCID: PMC8708297 DOI: 10.3390/ph14121205
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Scheme 1Structure of the TXA-ACN protonated adduct formed by positive-mode electrospray ionization and the two possible protonation sites of tranexamic acid.
Figure 1ESI-MS scan spectra obtained for TXA using (A) acetonitrile-aqueous ammonium bicarbonate (pH 7.4; 10 mM) (80:20, v/v) and (B) acetonitrile-aqueous ammonium bicarbonate (pH 7.4; 10 mM) (50:50, v/v) as mobile phase.
Influence of mobile phase composition in TXA-ACN protonated adduct formation.
| ACN Mobile Phase Composition (%, | [M + H]+/[M + ACN + H]+ Ratio (%) | |
|---|---|---|
| Flow Injection | Chromatography | |
| 80 | 21.4 ± 1.5 I | 10.5 ± 0.1 II |
| 70 | 29.0 ± 1.9 III | 23.3 ± 1.4 IV |
| 60 | 39.4 ± 2.4 V | 29.5 ± 1.7 VI |
| 50 | 54.7 ± 4.2 VII | 33.8 ± 0.1 VIII |
I–VIII Comparison between the mean ratio [M + H]+/[M + ACN + H]+ values obtained using flow injection analysis and chromatography. Different superscript numbers indicate that statistically significant differences were observed (p < 0.05).
Figure 2Product ion spectra (CID-MS/MS) obtained at CE of −10 V of the selected precursor ions (A) [M + H]+ at m/z 158.25 and (B) [M + ACN + H]+ at m/z 199.30.
Scheme 2Gas-phase formation of [M + H]+ and [M + ACN + H]+ and its fragmentation pathway.
Figure 3Optimized geometries M06-2X/6-31+G(d,p) level of the [M + ACN + H]+ adduct (2) in the gas phase (left) and in acetonitrile (right).
Figure 4Calculated energies of the [M + ACN + H]+ species in the gas phase (black) and in the solvent environment (blue) relative to the energy of adduct 2.
Scheme 3Gas-phase reaction of TXA with ethylnitrilium ion producing acetonitrile derivatives 7a and 7b.
Figure 5Optimized structures at M06-2X/6-31+G(d,p) level of the adducts 7a (top) and 7b (bottom) in acetonitrile environment with the length of the elongated bonds.
Figures of merit of the proposed UHPLC-MS/MS method for quantification of TXA based on the [M + ACN + H]+ adduct ion and comparison with the analytical parameters obtained using the pseudo-molecular [M + H]+ ion.
| Parameters | Precursor ion [M + ACN + H]+
| Precursor ion |
|---|---|---|
| Linear range (ng mL−1) | 30–600 | 30–600 |
| Calibration curve | y = 0.00291 (±0.00003) x + 0.026 (±0.009) | y = 0.00296 (±0.00002) x + 0.035 (±0.007) |
| Correlation coefficient ( | ≥0.9983 | ≥0.9974 |
| LOD (ng mL−1) a | 3 | 18 |
| LOQ (ng mL−1) a | 6 | 36 |
| Precision (CV, %) b | ||
| Intra-day | 0.6 | 1.7 |
| Inter-day | 2.4 | 1.7 |
| Accuracy (%) b | ||
| Intra-day | 94.7 | 96.3 |
| Inter-day | 92.2 | 94.7 |
| Recovery (%) c | ||
| TXA | 98.8 ± 0.5 I | 96.3 ± 3.6 I |
| TXA-IS | 100.6 ± 1.0 II | 94.4 ± 1.0 III |
| Matrix factor (%) d | ||
| TXA | 105.4 ± 3.5 IV | 110.0 ± 7.6 IV |
| TXA-IS | 103.6 ± 6.9 V | 110.0 ± 6.3 V |
| IS normalized matrix factor e | 102.0 ± 5.4 VI | 100.0 ± 1.4 VI |
LOD, limit of detection; LOQ, limit of quantification; CV, coefficient of variation; TXA, tranexamic acid; IS, internal standard, 13C2,15N,trans-tranexamic acid; a LOD and LOQ values in plasma samples; b Precision and accuracy estimated in plasma extracts spiked with 300 ng mL−1 TXA (corresponding to 1800 ng mL−1 in plasma); c Recovery (mean ± CV, n = 2) assessed by spiking plasma samples with 1800 ng mL−1 of TXA and IS before extraction and sample processing; d Matrix effect (mean ± CV, n = 6) assessed by the post-extraction addition method, at 300 ng mL−1 concentration level (in plasma extract); e IS normalized matrix factor calculated by division of the matrix factor of the analyte by the matrix factor of the IS; I–VI Comparison between the experimental means obtained for the different analytical parameters. The same superscript number indicates that no statistically significant difference was found for the results obtained by the two quantification methods (p < 0.05).
Concentration of TXA (µg mL−1) in plasma samples collected from paediatric patients undergoing scoliosis surgery, determined using the pseudo-molecular [M + H]+ ion or the [M + ACN + H]+ adduct for quantification.
| Plasma Samples a | ||
|---|---|---|
| End of surgery | ||
| Patient 1 | 10.9 ± 0.1 I | 11.2 ± 0.1 I |
| Patient 2 | 15.7 ± 0.1 II | 16.0 ± 0.1 II |
| Patient 3 | 17.1 ± 0.5 III | 17.1 ± 0.2 III |
| Patient 4 | 14.0 ± 0.3 IV | 14.2 ± 0.1 IV |
| Patient 5 | 9.8 ± 0.1 V | 10.0 ± 0.1 V |
| 24 h after surgery | ||
| Patient 1 | 0.213 ± 0.001 VI | 0.219 ± 0.002 VI |
| Patient 2 | 0.226 ± 0.001 VII | 0.229 ± 0.001 VII |
| Patient 3 | 0.325 ± 0.002 VIII | 0.332 ± 0.002 VIII |
| Patient 4 | 0.214 ±0.004 IX | 0.226 ± 0.006 IX |
| Patient 5 | 0.269 ± 0.004 X | 0.275 ± 0.001 X |
a Each value corresponds to the mean ± standard deviation (n = 2). Prior to analysis by UHPLC-MS/MS, sample extracts collected at the end of surgery were diluted 20 times in mobile phase; I–X Comparison between the mean TXA concentration values determined in clinical plasma samples. The same superscript number indicates that no statistically significant difference was found for the results obtained by the two quantification methods (p < 0.05).
Figure 6Representative chromatograms of a plasma extract from a patient before drug administration (A), spiked with 300 ng mL−1 TXA (B), and a plasma sample (35.7 ng mL−1 TXA in extract) collected from a patient undergoing scoliosis surgery (C).